Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Autonomix Medical, Inc. (NASDAQ: AMIX) Just Landed Back On Our Watchlist For Tomorrow Morning
—Wednesday, September 30, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Get (AMIX) On The Radar Before Tomorrow Morning… September 29, 2026 Dear Reader, The global neuromodulation devices sector is on a trajectory that demands attention… According to Grand View Research, the worldwide neuromodulation devices market is expected to grow from $7B in 2026 to nearly $14B by 2033, expanding at a CAGR north of 10%. That kind of growth draws attention for good reason. Chronic pain remains one of the most undertreated conditions on the planet, and the medical community has spent decades searching for something better than opi-oids and blind ablation procedures. The challenge has always been precision. Physicians know the nerves are there. They know which ones are causing the pain. But until now, the technology to see those nerves in real time — to target them individually and confirm the treatment worked before the procedure is over — simply didn't exist. That's what makes Autonomix Medical, Inc. (NASDAQ: AMIX) worth a closer look right now. This company has built something genuinely different… A first-in-class catheter-based microchip sensing array — powered by a proprietary ASIC chip — that can detect and differentiate neural signals below 5 microvolts. To put that in context, conventional cardiac sensing technologies bottom out around 100 microvolts. Autonomix's platform operates at a level of sensitivity that existing technologies simply cannot reach. And the early clinical data suggests that sensitivity translates into real results for real patients. Autonomix Medical, Inc. (NASDAQ: AMIX) will be topping our watchlist tomorrow morning—September 30, 2026.
According to Yahoo Finance, (NASDAQ: AMIX) has a float of less than 900K shares listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift. In a coverage listing published last week, Maxim Group analyst Anthony Vendetti maintained a $42 target on (AMIX) with a bullish momentum rating — a figure that suggests significant upside from the $3.80 range where shares have recently been changing hands. What Happens When a Machine Can Actually See a Nerve Fire
The core of what Autonomix has built is a three-step procedural framework the company calls "Sense, Treat and Verify." Step one: the platform maps neural activity in real time to identify overactive nerves. Step two: an advanced ablation catheter delivers targeted thermal energy to those specific nerves. Step three: the system provides immediate intra-procedure feedback confirming the treatment worked. That third step is the one that separates this from everything else on the market… Today, nerve ablation procedures are performed essentially blind. Physicians target an area, deliver energy, and hope for the best. There's no way to confirm during the procedure whether the right nerves were reached, whether the ablation was sufficient, or whether surrounding tissue was affected. Autonomix's system could change that entirely — giving clinicians the ability to see what they're targeting, confirm they've hit it, and verify the result before the patient leaves the table. 
The proprietary sensory microchip sits just 1-2 millimeters from a custom antenna array, which means the signal only has to travel a few millimeters rather than through layers of tissue. That preserves signal integrity and data resolution at a level the company says no other commercially available device can match. Multi-channel signaling allows for 360-degree positioning for directional neuronal targeting. The proof-of-concept data from the company's PoC 1 study in pancreatic cancer pain is striking… According to the company's September 2026 corporate presentation, 100% of femoral-access patients responded to the procedure. At three months post-procedure, responding patients showed a mean 65.6% reduction in VAS pain scores — well beyond the 20% threshold considered clinically significant. Perhaps the most compelling data point: 100% of responders at three months reported zero opi-oid use. And 77% showed improvement in global quality of life. These numbers came from patients with late-stage pancreatic cancer — a population where pain is typically severe, relentless, and resistant to conventional approaches. No device-related or procedure-related serious adverse events were reported across the study. Pain relief occurred as early as 24 hours post-procedure, with results remaining consistently positive at 7 days and 4-6 weeks before holding strong through the three-month follow-up window. The company's follow-on PoC 2 study is now underway, expanding the work into additional visceral cancers — stomach, liver, and bile duct — as well as earlier-stage pancreatic cancer patients. That expansion is worth paying attention to, because the broader pain management market represents a massive addressable space… A Patent Portfolio That Keeps Getting Stronger
A technology this differentiated needs strong IP protection, and Autonomix Medical, Inc. (NASDAQ: AMIX) has been building exactly that. The company now holds 120-plus patents issued and pending across its platform. In just the past two months, the momentum has accelerated… In August, the USPTO issued U.S. Patent No. 12,433,670, covering systems designed to sense, map, and selectively target nerves associated with tumors, cancer-related pain, and organ function. That patent describes potential applications across pancreatic, prostate, breast, colorectal, liver, ovarian, and bone cancers — underscoring the platform nature of this technology. Days later, the company announced the issuance of U.S. Patent No. 12,714,780, which broadens protection around feedback-guided precision neuromodulation and targeted therapy delivery — including neural ablation for cancer pain. The underlying technology traces back to applications originally filed in 2012 and 2014, reflecting over a decade of foundational development. Then in September, a European patent was granted covering autonomic nervous system assessment technologies, expanding the company's international IP footprint across Europe. CEO Brad Hauser described the European grant as "another important step in expanding our global intellectual property footprint" and called building a broad international patent portfolio "a key strategic priority." On the regulatory side, the company completed its Good Laboratory Practice (GLP) preclinical study in August — a significant milestone on the path toward FDA submission. Final histopathology and laboratory analyses supported the study's safety and performance objectives. Hauser called the GLP completion "a critical step in our regulatory and clinical development strategy" that "reinforces the positive safety and performance profile we have observed throughout the study." The company is targeting a Class II De Novo FDA clearance in 2028, with IDE clinical trials planned for the U.S. ahead of that submission. The combined addressable market across the company's target indications — pain management, hypertension, and COPD — totals more than $100B according to the company's corporate presentation. The Board Just Got a Lot More Interesting
The caliber of the people surrounding this company is hard to ignore… In September, Autonomix Medical, Inc. (NASDAQ: AMIX) appointed Sandra Cohen Kalter to its Board of Directors. Kalter served as Vice President and Chief Regulatory Counsel at Medtronic for 20 years, where she oversaw due diligence and integration activities for more than 27 acquisitions. Her experience includes some of Medtronic's most significant platforms — Symplicity Spyral Renal Denervation, Evolut TAVR, Micra Transcatheter Pacing System, and PulseSelect Pulsed Field Ablation. Renal denervation experience specifically is deeply relevant to Autonomix's transvascular neuromodulation approach. When someone with that background joins a development-stage medtech board, it signals something about where the company may be heading strategically… Chairman Walter Klemp noted that Kalter's "firsthand understanding of how a global medical device leader evaluates emerging technologies, navigates regulatory pathways and approaches strategic partnerships and acquisitions is exceptionally valuable." Meanwhile, Autonomix's Co-Founder and Chief Medical Officer, Dr. Robert Schwartz, was named the recipient of the 2026 Cardiovascular Tech Forum Lifetime Achievement Award. Dr. Schwartz has authored more than 500 scientific publications, holds more than 200 patents, and co-invented the Watchman device — which Boston Scientific later acquired and turned into a franchise generating over $1B in annual revenue. The broader leadership team carries its own track record: multiple members were involved in exits to AbbVie ($550M) and Allergan ($2.4B). And in early September, two scientific abstracts were accepted for poster presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress in Copenhagen — further demonstrating that the broader medical community is paying attention to this technology. 7 Reasons Why We’ll Be Watching (AMIX) Tomorrow Morning — Wednesday, September 30, 2026…
1. Small-Float: With less than 900K shares listed as available to the public, AMIX’s small float could have the potential for big moves if demand begins to shift. 2. First-in-Class Neural Sensing: The company's proprietary catheter-based microchip can detect neural signals below 5 microvolts — a level of sensitivity that conventional technologies cannot match, enabling precision nerve targeting for the first time. 3. Proven Pain Reduction in PoC 1: Responding femoral-access patients in the pancreatic cancer PoC 1 study showed a 65.6% reduction in VAS pain scores at three months, with 100% of those responders reporting zero opi-oid use. 4. GLP Preclinical Study Completed: The company successfully completed its GLP preclinical study in August 2026, a key regulatory milestone supporting its planned FDA submission and De Novo clearance pathway targeting 2028. 5. Rapidly Expanding IP Portfolio: With 120-plus patents issued and pending — including three new patents granted across the U.S. and Europe in just the past two months — the company is building a formidable IP moat around its precision neuromodulation platform. 6. Former Medtronic Regulatory Chief Joins the Board: The appointment of Sandra Cohen Kalter, who spent 20 years at Medtronic overseeing 27-plus acquisitions and working on category-defining technologies like renal denervation, adds deep regulatory, clinical, and strategic M&A expertise. 7. Award-Winning Scientific Leadership: Co-Founder and CMO Dr. Robert Schwartz — recipient of the 2026 CTF Lifetime Achievement Award — brings 500-plus publications, 200-plus patents, and the co-invention of the Watchman device to the company's foundation. Get (AMIX) On The Radar Before Tomorrow Morning… 
The neuromodulation space is growing fast, the clinical data is encouraging, and the intellectual property wall keeps getting taller… Autonomix Medical, Inc. (NASDAQ: AMIX) is building a precision nerve-sensing and treatment platform that could reshape how clinicians approach pain and nervous system disorders — and doing it with a leadership team that has been here before. For anyone following the medtech space closely, this is a name that deserves attention. We will have all eyes on Autonomix Medical, Inc. (NASDAQ: AMIX) first thing tomorrow morning. Get (AMIX) on the radar before you shut down for the night. Sincerely, Jeff Ackerman
Managing Editor,
Stock News Trends |
Tidak ada komentar:
Posting Komentar